| (-)-Epigallocatechin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| (2R)-RXP470.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| (E)-N-(3-Methoxyphenyl)cinnamamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-MMP408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| (R)-ND-336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-Prinomastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| (R)-TAPI-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-AAA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-Tanomastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S,S)-TAPI-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S,S)-TAPI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| o-Phenanthroline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| o-Phenanthroline-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 10-Butyl Ether Minocycline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 14-3-3-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| 2,5-Dihydroxy-4-methoxyacetophenone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| 2-Methoxy-2,4-diphenylfuran-3-one |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Methylisothiazolinone hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Methylisothiazolinone-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| 20(R)-Ginsenoside Rh2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Alisol B 23-acetate (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Alisol B 23-acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| 23-Hydroxybetulinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| 264RAD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3,3′-Bisdemethylpinoresinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Gallic aldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| 3,5,7-Trimethoxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| 3-Aminobenzene-1,2-diol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 3-Aminopropionitrile fumarate (2:1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| 3-Ethyltoluene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-Hydroxy-2-pyrone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-DAMP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| 4-Epianhydrochlortetracycline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-Methoxytryptophol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| 6-epi Doxycycline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| 7-Methoxy-1-tetralone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| 8-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Abametapir |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| ABT-518 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABT-770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABX-MA1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetyl zingerone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| AChE-IN-51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Actinonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.37% |
| ADAM-17 Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADAM-17 Substrate TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| ADAM10 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adam10 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADAM10 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADAM17 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adam17 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adam17 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADAM17-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADAM8-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Adenosine receptor antagonist 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aderamastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Aderbasib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Aderbasib-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AG01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.10% |
| AG73 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ageladine A dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGG-523 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| AGPS-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| AK-778-XXMU |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Alisol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Alisol A (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alpha 1(I) Collagen (614-639), human |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| Anti-ADAM17 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ADMAST4 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD146 Antibody (AA98) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Human/Mouse denatured collagen type-I Antibody (XL313) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95% |
| Anti-Human/Mouse/Bovine ADAM10 Antibody (8C7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL11RA Antibody (X209) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.75% |
| Anti-MMP-16 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-MMP9 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-osteoporosis agent-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-TIMP-1 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| anti-TNBC agent-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibacterial agent 315 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 183 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 204 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-132 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apigenin-7-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Apoptosis inducer 44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apratastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| ARP-100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| ARP101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| ASPH-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AZD-1236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Barakol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BAY-7598 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BE-16627B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berkeleyamide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berkeleyamide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BHQ-3 carboxylic acid chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.0% |
| BI-4394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| BIM-46174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BJ-2302 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BPHA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| BPU |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| BR351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BR351 precursor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BRK/PTK6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BSc2118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BT1769 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BT1769 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Buloxibutid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Buloxibutid hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C-telopeptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C-telopeptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| Candidalysin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Candidone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Carbobenzoxyproline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Cardanol monoene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Cathepsin G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CCKBR agonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| CD1530 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| CGS 27023A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CGS 27023A free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chamazulene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Chloramphenicol/BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIL-102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cipemastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| cis-ACCP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| CKD-712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CL-82198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| CL-82198 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CM-352 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CMC2.24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.11% |
| Colchicine derivative-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Colchicine-O-CO-Enyl(Me)-Enyl-Enyl(Me)-Enyl-1,3,3-trimethylcyclohex-1-ene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagen Type II Fragment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| Communic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CP-471474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| CP-544439 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CPA 926 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CQ-Mito |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CTS-1027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| CTTHWGFTLC, CYCLIC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CTTHWGFTLC, CYCLIC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.52% |
| cyclo(RLsKDK) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| cyclo(RLsKDK) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Cystatin B agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CZh226 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D-Isofloridoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| D-Mannuronic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| D8P1C1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DB04760 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| DC-Y13-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| DH-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DHW-221 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethanolamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Diethanolamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethyl pyimDC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethyl-pythiDC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Diplacone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| DL-erythro-Dihydrosphingosine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Dnp-PLGLWA-DArg-NH2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Dnp-PLGLWAr-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dnp-PYAYWMR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DOTA-GA-maleimide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Doxycycline calcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DP-b99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| E09241 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endothelin 1 (swine, human), Alexa Fluor 488-labeled |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eulophiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Eupatorin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Excisanin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| F81-1144b |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FBIN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Feprazone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| FFAGLDD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FFAGLDD TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Flocoumafen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Fluoxetine-Conjugated Platinum(IV) prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FN-439 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FN-439 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| FSL-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| FT011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Funalenone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganoderic acid Mk |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GCRRGPLGLSLGKRRCG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GI-129471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GI254023X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Ginsenoside F4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| GIP (22-51) human |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GM1489 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPLGIAGQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| GPLGIAGQ TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| GPLGIAGQC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPLGLAGGWGERDGS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| GPLGVRG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPLGVRGC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Guluronic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| GW-3333 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GW280264X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Halociline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hepcidin-1 (mouse) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hepcidin-1 (mouse) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Hexapeptide-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Highly purified Type II collagen, from goat articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type II collagen, from sheep articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type V collagen, from human placenta |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hippuric acid-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HNHA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| HSP110-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrangenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| IDE-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagen petide Type II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL13Rα2 D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| INCB3619 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Incyclinide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| Indinavir-13C4,15N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inotodiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| Isozedoarondiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IVMT-Rx-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Izeltabart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Collagen, Type I, from bovine achilles tendon |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagen petide Type I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JG26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| JNJ0966 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| JNK-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KAFDITYVRLKF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KB-R7785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| KD014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.98% |
| KP-457 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| KP-457 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-Val-P |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LAS190792 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levamlodipine hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levamlodipine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LIFR/GPBAR1 modulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Linvemastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Lixisenatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Loliolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| LQB-118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Luteolin 7-O-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| LXJ-02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lysyl-phenylalanyl-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Matlystatin D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Matlystatin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Matlystatin F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-KPLGL-Dap(Dnp)-AR-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-PLAQAV-Dpa-RSSSR-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Mca-PLAQAV-Dpa-RSSSR-NH2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Mca-Pro-Leu-Ala-Cys(Mob)-Trp-Ala-Arg-Dap(Dnp)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-Pro-Leu-Ala-Cys(Mob)-Trp-Ala-Arg-Dap(Dnp)-NH2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-Pro-Leu-Gly-Leu-Glu-Glu-Ala-Dap(Dnp)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| MEDI-3622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Methyl rosmarinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| MG-3C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-1903 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| MMP Inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP Inhibitor II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| MMP-1 Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| MMP-1/MMP-9 Substrate, Fluorogenic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| MMP-11-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-13 Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-13 Substrate TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-13-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-2 Inhibitor I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| MMP-2 Inhibitor II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| MMP-2 Inhibitor-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-2/9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-2/9-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-2/MMP-9 Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| MMP-2/MMP-9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| MMP-7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| MMP-7-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| MMP-7-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| MMP-8 inhibitor-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| MMP-8/MMP-26 Fluorogenic substrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| MMP-9-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| MMP-9-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| MMP-9-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| MMP-9/10-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP-9/10-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| MMP-9/MMP-13 Inhibitor I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| MMP1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP10 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp10 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp10 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP12 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp12 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp12 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP12-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP13 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp13 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp13 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP13-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| MMP13-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP13-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP13-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP14 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp14 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp14 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP145 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| MMP2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| MMP2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| MMP2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP3 inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| MMP3 inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP3 inhibitor 3 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP3-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| MMP7 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp7 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp7 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP8 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp8 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp8 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMP9 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp9 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mmp9 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMPI-1154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| MOCAc-PLGL(Dpa)AR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| m-PEG2000-NHS ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.89% |
| MT5-MMP-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Myoferlin inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| NAMI-A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| NBD-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys-(DMC)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ND-322 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| ND-336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.16% |
| ND-378 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Negundoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEO212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NFF-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NFF-3 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.32% |
| NNGH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.6% |
| Nordentatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NRMA-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 405020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| NSC45586 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Nudol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| o-Phenanthroline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| OART |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ONO-4817 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| OPB-3206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Otaplimastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Otaplimastat hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P2X7R antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PAI-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Palmitoyl tripeptide-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PD-166793 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| PD-166793 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDZ1i |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Peptide 74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.50% |
| PF-00356231 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-00356231 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| PG 116800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Phloroglucinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| PI3K/AKT-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| PI3Kδ-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pipoxolan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pipoxolan hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PLGLAG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| PNU-248686A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Porphyra 334 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| PPNDS tetrasodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
89.0% |
| Prinomastat hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Pro-Leu-Gly-NHOH hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| proMMP-9 inhibitor-3c |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| proMMP-9 selective inhibitor-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC DDR1 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| PT109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| PTIQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PXS-4728A free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pyridoxatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PythiDC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| PZ-1657 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PZ-1657 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-130823 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RANKL-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rebimastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RH01617 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rhamnose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Rhamnose monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| RJF02215 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RLVT-14-02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ro 31-9790 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Ro 32-7315 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO-28-2653 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO314724 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ROCK2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RS-104966 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.39% |
| RuDiOBn |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RXP03 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.82% |
| RXP470.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| S 3304 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| S 3304 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| S-methyl-KE-298 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Safironil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| SB-3CT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| SC-44463 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SC-77964 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SCAL-255 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| SD-2590 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.4% |
| SD-7300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SDH-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SDH-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SEMBL |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| SH491 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SKLB-Y13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| SM-7368 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Smyrindiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Snail IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| Solimastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ST09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STK899704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sucrose octasulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| T 26c sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| T-26c |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| T-5224 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| T-5224-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAK-756 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAK-778 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Talopeptin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tanomastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| TAPI-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.06% |
| TAPI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| TAPI-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.41% |
| TAT (47-57) GGG-Cys(Npys) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-QFNP12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-QFNP12 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.90% |
| Tenidap |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| TG-MMP-Lys |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGGGPLGVARGKGGC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thunberginol C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tianeptine-d6 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TMI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| TNO003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNO003 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNO211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| TNO211 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Torulene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP0556351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP0597850 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| TP0628103 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP0628103 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Tranexamic acid-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRAP-14 amide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tremulacin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.41% |
| Trifloroside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trilinolein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Trilinolein (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trilinolein-13C54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trilinolein-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TU-100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin/MMP-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin/MMP-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin/MMP-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U27391 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UK 356618 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| UK-370106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.70% |
| VDR agonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vorbipiprant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| VPLSLYSG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WAY-151693 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WAY-170523 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XL-784 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| XL-784 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YH-306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| YYRADDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-PDLDA-NHOH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Z-VRPR-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| ZG36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZM-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α-Glucosylrutin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.32% |
| α-Neoendorphin (porcine) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α-Solanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| β-Anhydroicaritin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| β-Neo-Endorphin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Lixisenatide (Leu-13C6,15N) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triolein-13C3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Triolein-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Triolein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| H-Gly-Pro-Hyp-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Salvianolic acid A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Salvianolic acid F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Coriolus Versicolor Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sodium Selenite |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Ilomastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Edaravone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Edaravone-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Endoproteinase Asp-N (MS grade) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gaultherin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Demethylwedelolactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Guluronic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Imidapril |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Tianeptine-d12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tianeptine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Tianeptine sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Kukoamine B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Kukoamine B-d5 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kukoamine B mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Matrix metalloproteinase 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Karacoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Doxycycline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| Doxycycline-d3 (hyclate) (major) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline hyclate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Andecaliximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| Histatin 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Histatin 5 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| p-Aminophenylmercuric acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Murine Thrombin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Murine Fibrinogen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levamlodipine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.06% |
| Levamlodipine-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Batimastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Batimastat sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| Isobutanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Isorhapontigenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Isoviolanthin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Isoviolanthin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isofraxidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Isoginkgetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Hinokiflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ecliptasaponin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Prinomastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| Flavanone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Saikosaponin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| Kuwanon G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| (+)-Medioresinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Quercimeritrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Auraptene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Propoxur (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| Propoxur-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Propoxur-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Propoxur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Bimatoprost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Polygalacic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Tranexamic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Cyanidin 3-sambubioside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Chloramphenicol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Threo-Chloramphenicol-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Glaucine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Ganoderma Lucidum/Reishi Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.20% |
| Inotilone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arctigenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Canine Thrombin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Swertiamarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Regaloside C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Licoricidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Stevia Powder |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Methacrylated Type I collagen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Methylisothiazolinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Sorafenib tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Rilpivirine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Imidapril-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Imidapril hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Doxycycline-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Phellodendrine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Edaravone sulfate-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Indinavir sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Chondroitin sulfate (from chicken) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Chondroitin sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| Chondroitin sulfate sodium (from shark cartilage) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Phosphoramidon |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phosphoramidon disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Chymotrypsin, Human Pancreas |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sorafenib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Sonelokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Viridicatol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Vitamin CK3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Vitamin CK3 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Vicenin 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Meloxicam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Meloxicam-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meloxicam sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chymotrypsin (MS grade) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chymotrypsin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagen proline hydroxylase inhibitor-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase I, from Clostridium histolyticum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase IV, Clostridium histolytica |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type V |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type VI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagenase, Type VII |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aloin (mixture of A&B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Isoliquiritin apioside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Sotetsuflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phenyl β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Levamlodipine besylate Hemipentahydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levamlodipine besylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Indinavir |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Indinavir sulfate ethanolate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anethole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Morroniside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Cynaropicrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Sucrose octasulfate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Sucrosofate potassium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Cordycepin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Epitheaflagallin 3-O-gallate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Cetrimonium bromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Stigmasterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Stigmasterol-d5-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Stigmasterol-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.05% |
| Lucideric acid A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Lucidenic acid C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Coenzyme Q0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Damulin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid-BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lixisenatide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Ginkgolide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Apomorphine (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apomorphine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Apomorphine hydrochloride hemihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Hippuric acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Sodium hippurate, 98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Marimastat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Homoeriodictyol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Highly purified Type III collagen, from human placenta |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type III collagen, from bovine skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.0% |
| Highly purified Type III collagen, from porcine skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type II collagen, from human sternal cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Highly purified type II collagen, from rat sternal cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type II collagen, from mouse sternal cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type II collagen, from porcine articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type II collagen, from chick sternal cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Highly purified Type IX collagen, from bovine articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type IX collagen, from porcine articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type IX collagen, from chick articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from human placenta |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from rabbit skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from rat skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified type I collagen, from mouse skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from canine skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from porcine skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type I collagen, from chick skin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type V collagen, from human amnion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type V collagen, from mouse intestine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type V collagen, from bovine amnion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type XI collagen, from human sternal cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type XI collagen, from bovine articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Highly purified Type XI collagen, from porcine articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90% |
| Highly purified Type XI collagen, from chick articular cartilage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Flavokawain B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Phellodendrine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Astragaloside IV |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Type I Collagen, from rat tail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥90% |
| Hecogenin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |